Anti-Interleukin-6 (Tocilizumab) Therapy in Takayasu?s Arteritis: Real Life Experience.
Tumor necrosis factor inhibitors (TNFi) and anti-interleukin 6 (anti-IL-6) therapies are increasingly being used in Takayasu?s Arteritis (TA) patients unresponsive to corticosteroids ± conventional immunosuppressive agents. The aim of this study was to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life. Fifteen (86.7% female) TA patients who received at least three cycles of tocilizumab therapy were retrospectively assessed using clinical, laboratory and radiological evaluation before and after tocilizumab therapy. The median (min-max) age of the patients at evaluation was 35 (20-58) years and the median disease duration from diagnosis was 24 (12-168) months. The median (min-max) duration of follow-up after tocilizumab was 15 (3-42) months. There a was significant decrease in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and visual analog scales (VAS)-patient-global of patients after tocilizumab therapy; median (min.-max.) ESR [26 (5-119) vs. 3 (2-49) mm/h, p = 0.02], CRP [39.8 (2.4-149.0) vs. 7.9 (0-92,9) mg/L, p = 0,017], VAS-patient-global [50 (0-90) vs. 30 (0-60), p = 0,027], respectively. In 8 patients ERS and CRP levels were in the normal range at last control. Imaging modalities after tocilizumab were available in 9 patients; 8 patients were radiologically stable and regression was seen in one patient. Comparable imaging modalities before and after tocilizumab were available in 5 patients; 4 patients were radiologically stable and regression was seen in one patient. Radiologic findings were consistent with laboratory response. Glucocorticoids dosage decrease from a mean dosage of 16.2 (9.1) mg/day at baseline to 7.1 (3.8) mg/day (p=0.001) at last follow-up visit. There was no increase in steroid dosage in any patient. All patients well tolerated Tocilizumab. Based on retrospective real-life data, anti-IL-6 (tocilizumab) appears to be an effective and tolerable treatment option in refractory TA patients.